Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole: Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics

  title={Asenapine, Blonanserin, Iloperidone, Lurasidone, and Sertindole: Distinctive Clinical Characteristics of 5 Novel Atypical Antipsychotics},
  author={Sheng-Min Wang and Changsu Han and Soo-Jung Lee and Ashwin A. Patkar and Prakash S. Masand and Chi-Un Pae},
  journal={Clinical Neuropharmacology},
AbstractSchizophrenia is a serious, chronic, and devastating mental illness with a substantial impact on psychological, physical, social, and economical areas of an individual and society. To treat such critical mental illness, a number of first-generation (typical) and second-generation (atypical) antipsychotics are currently available in the market. Despite such treatment options, most of patients with schizophrenia have a poor treatment outcome and become treatment resistant, causing… 

Asenapine: A Review in Schizophrenia

Although potentially associated with more extrapyramidal symptoms, asenapine appears to have less weight gain and metabolic effects than some other antipsychotic agents, such as olanzapine.

Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study

  • Yongmin KimSheng-Min Wang W. Bahk
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2016
Patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability.

An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder.

It is demonstrated that adjunctive treatment with asenapine may provide additional benefit to some patients experiencing residual PTSD symptoms in spite of optimal antidepressant therapy.

Transdermal Delivery of Antipsychotics: Rationale and Current Status

The aim of this article is to provide the rationale for the development of transdermal formulations of antipsychotics by highlighting their main advantages, starting with an overview of the

Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review

The PRL propensity of the different second-generation and newly approved APs is described to describe the prevalence rates of SDs associated with these compounds in patients with schizophrenia and treatment strategies for the management ofSDs and/or hyperprolactinemia (HPRL).

Antipsychotic Polypharmacy in Treatment of Schizophrenia; Should or Should Not?

  • C. Pae
  • Psychology, Medicine
    Chonnam medical journal
  • 2020
APP now deserves an evidence-based and acceptable treatment strategy, not an empirical or preferential treatment approach for treatment of schizophrenia in contemporary clinical practice.

New drugs for the treatment of agitation in schizophrenia: a systematic review and meta-analysis of inhaled loxapine and infused sodium nitroprusside

The efficacy data showed superiority of LOXi against placebo, regardless of the dose, and treatment with NIT showed favorable results, with significant reduction of the symptoms.

A Review of the Pharmacological and Clinical Profile of Newer Atypical Antipsychotics as Treatments for Bipolar Disorder: Considerations for Use in Older Patients

Research data from open-label studies on oral asenapine and aripiprazole as add-on therapy suggest that these two agents are adequately tolerated and improved symptoms of depression and mania in OABD; hence, there is an urgent need to conduct RCTs onThese two agents.



Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults

  • W. Bobo
  • Medicine, Psychology
    Expert review of clinical pharmacology
  • 2013
For each drug, comparative and real-world effectiveness studies are lacking, as are effectiveness and safety data in elderly, young and pregnant/nursing patients, and the exact place of iloperidone, asenapine and lurasidone within the broader antipsychotic armamentarium is currently difficult to establish.

The Efficacy and Safety of Blonanserin Compared with Haloperidol in Acute-Phase Schizophrenia

Boonserin was effective in the treatment of acute schizophrenia and showed greater efficacy in negative symptoms compared with placebo and haloperidol, and blonanserin (5 and 10 mg) was more effective against the negative symptoms than haloperIDol.

Asenapine: a clinical overview.

  • S. Potkin
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2011
Asenapine is a new, second-generation antipsychotic medication with demonstrated efficacy for the acute and maintenance treatment of schizophrenia and may be a helpful treatment option for patients with schizophrenia when weight gain, dyslipidemia, and endocrine abnormalities are a concern.

Iloperidone: A new drug for the treatment of schizophrenia.

  • Sally A. ArifMelissa Mitchell
  • Medicine, Psychology
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents.

Asenapine: a clinical review of a second-generation antipsychotic.

Blonanserin: a review of its use in the management of schizophrenia.

Clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy.

Iloperidone for the management of adults with schizophrenia.

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

Asenapine was effective and well tolerated in patients with acute schizophrenia and may provide a new option for control of negative symptoms.

Clinical potential of lurasidone in the management of schizophrenia

Lurasidone differs from the other second-generation antipsychotics by having a good tolerability profile, in particular for cardiometabolic tolerability, but seems to have a significant although moderate link with the occurrence of akathisia, extrapyramidal symptoms, and hyperprolactinemia at the start of treatment.

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.

The results of this study suggest that the novel psychotropic agent lurasidone is a safe and effective treatment for patients with an acute exacerbation of schizophrenia.